SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 26.66-1.8%Oct 29 3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mr. Pink who wrote (5695)8/25/2000 8:50:20 PM
From: Peter V  Read Replies (1) of 5736
 
Slow trading day today, only 10 times normal volume. I guess the following PR didn't help much, got down to under 1 1/2. Sorry I wasn't paying attention, I was busy watching my EMLX bounce around like a pinball.

Friday August 25, 8:16 am Eastern Time
Press Release

SOURCE: Chromatics Color Sciences International, Inc.
Chromatics Color Sciences International, Inc. Responds to Market Activity

NEW YORK, Aug. 25 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI - news) announced today that the recent large volume of trading and the decline in the Company's stock price was not due to any adverse event in the Company, its operations or business affairs.

Brian Fitzpatrick, the CEO of CCSI, stated, ``Following the recent transition in management announced earlier this month, I will be holding an Investors' Conference Call after Labor Day to articulate the strategic directions developed by the new management team relative to the Company's next phase of expanding commercial market applications.''

Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties in this field. The Company has received clearance from the Food and Drug Administration (FDA) for the commercial use of its medical device for the non-invasive monitoring of bilirubinemia in newborn infants by healthcare professionals in hospitals, clinics, pediatrician offices and the home environment. The Company believes its technologies and intellectual properties may also have medical applications in the detection and monitoring of other chromogenic diseases which the Company defines as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. Medical applications, in addition to the non-invasive monitoring of bilirubinemia in newborns, will require additional clinical trials and FDA clearances for commercial use.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext